Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 19, 2022

SELL
$223.92 - $287.77 $173,761 - $223,309
-776 Closed
0 $0
Q3 2021

Oct 13, 2021

SELL
$282.99 - $369.05 $42,448 - $55,357
-150 Reduced 16.2%
776 $220,000
Q2 2021

Jul 22, 2021

SELL
$259.0 - $414.71 $172,235 - $275,782
-665 Reduced 41.8%
926 $321,000
Q1 2021

Apr 14, 2021

SELL
$242.95 - $284.63 $14,577 - $17,077
-60 Reduced 3.63%
1,591 $446,000
Q2 2020

Jul 15, 2020

SELL
$258.66 - $342.55 $103,464 - $137,020
-400 Reduced 19.5%
1,651 $442,000
Q1 2020

Apr 17, 2020

BUY
$268.85 - $341.04 $1,344 - $1,705
5 Added 0.24%
2,051 $649,000
Q4 2019

Jan 17, 2020

SELL
$220.06 - $304.07 $60,516 - $83,619
-275 Reduced 11.85%
2,046 $607,000
Q3 2019

Oct 11, 2019

SELL
$217.44 - $243.88 $56,534 - $63,408
-260 Reduced 10.07%
2,321 $540,000
Q2 2019

Jul 12, 2019

SELL
$219.29 - $241.72 $211,614 - $233,259
-965 Reduced 27.21%
2,581 $603,000
Q1 2019

Apr 29, 2019

SELL
$216.71 - $338.96 $692,821 - $1.08 Million
-3,197 Reduced 47.41%
3,546 $838,000
Q4 2018

Feb 05, 2019

SELL
$278.5 - $352.75 $66,840 - $84,660
-240 Reduced 3.44%
6,743 $2.03 Million
Q3 2018

Oct 17, 2018

SELL
$293.51 - $383.83 $280,889 - $367,325
-957 Reduced 12.05%
6,983 $2.47 Million
Q2 2018

Jul 16, 2018

BUY
$257.52 - $306.91 $14,421 - $17,186
56 Added 0.71%
7,940 $2.31 Million
Q1 2018

Apr 12, 2018

BUY
$260.13 - $367.91 $166,743 - $235,830
641 Added 8.85%
7,884 $2.16 Million
Q4 2017

Jan 26, 2018

SELL
$307.64 - $344.58 $130,131 - $145,757
-423 Reduced 5.52%
7,243 $2.31 Million
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $2.16 Million - $2.53 Million
7,666
7,666 $2.4 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Welch & Forbes LLC Portfolio

Follow Welch & Forbes LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Welch & Forbes LLC, based on Form 13F filings with the SEC.

News

Stay updated on Welch & Forbes LLC with notifications on news.